"Finally I will provide a very quick update on Glybera this is the first product whose active ingredient was derived from our platform to receive commercial approval, it's currently the only gene therapy product to receive approval in Europe. Glybera specifically indicated for the treatment of a subset of adult patients diagnosed with the orphan lipid disorder known as Lipoprotein lipase deficiency or LPLD, confirmed much by testing, these patients suffered from severe multiple episodes of pancreatitis despite dietary fat restriction. Glybera was developed by our licensee uniQure Biopharma being commercialized by uniQure's partner Chiesi, although we are not giving specific guidance about Glybera, we do understand that Chiesi has submitted price and reimbursement dossiers in key European countries to make Glyberia accessible to patients who will provide additional information as we receive it." ____________________________________________ http://seekingalpha.com/article/3424916-xenon-pharmaceuticals-xene-ceo-simon-pimstone-on-q2-2015-results-earnings-call-transcript?find=Glybera&all=false
Market Data 
Markets 
AI
